SLC6A14, a Pivotal Actor on Cancer Stage: When Function Meets Structure by L. Palazzolo et al.
For Peer Review
SLC6A14, a pivotal actor on cancer stage: when function 
meets structure
Journal: SLAS Discovery
Manuscript ID Draft
Manuscript Type: Original Research
Date Submitted by the 
Author: n/a
Complete List of Authors: Palazzolo, Luca; Università degli Studi di Milano, Dipartimento di Scienze 
Farmacologiche e Biomolecolari
Parravicini, Chiara; Università degli Studi di Milano, Dipartimento di 
Scienze Farmacologiche e Biomolecolari
Laurenzi, Tommaso; Università degli Studi di Milano, Dipartimento di 
Scienze Farmacologiche e Biomolecolari
Adobati, Sara; Università degli Studi di Milano, Dipartimento di Scienze 
Farmacologiche e Biomolecolari
Saporiti, Simona; Università degli Studi di Milano, Dipartimento di 
Scienze Farmacologiche e Biomolecolari
Guerrini, Uliano; Università degli Studi di Milano, Dipartimento di Scienze 
Farmacologiche e Biomolecolari
Gianazza, Elisabetta; Università degli Studi di Milano, Dipartimento di 
Scienze Farmacologiche e Biomolecolari
Indiveri, Cesare; Università della Calabria, Dipartimento di Biologia, 
Ecologia e Scienze della Terra
Anderson, Catriona; Newcastle University Institute for Cell and Molecular 
Biosciences, Faculty of Medical Sciences
Thwaites, David; Newcastle University Institute for Cell and Molecular 
Biosciences, Faculty of Medical Sciences
Eberini, Ivano; Università degli Studi di Milano, Dipartimento di Scienze 
Farmacologiche e Biomolecolari
Keywords: Computational chemistry, Pharmacology: ligand binding, receptor binding, amino acid transporter, molecular docking, molecular modelling
Abstract:
ATB0,+ (SLC6A14) is a sodium- and chloride-dependent neutral and 
dibasic amino acid transporter that regulates the distribution of amino 
acids across cell membranes. SLC6A14 is ubiquitous. The transporter is 
over-expressed in many human cancers characterized by an increased 
demand for amino acids; as such, it was recently acknowledged as a 
novel target for cancer therapy. The knowledge on the molecular 
mechanism of SLC6A14 transport is still limited, but some elegant 
studies on related transporters report the involvement in the transport 
mechanism of the symmetry of the 12 transmembrane α-helices, and 
describe structural rearrangements mediated by electrostatic interactions 
with some pivotal gating residues. 
In the present work, we constructed a SLC6A14 model in outward facing 
conformation via homology modelling and tested through molecular 
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dynamic simulation to predict amino acid residues critical for substrate 
recognition and translocation. We then docked the proteinogenic amino 
acids and other known substrates in the SLC6A14 binding site to study 
both gating regions and the exposed residues involved in transport. 
Interestingly, some of these residues correspond to those previously 
hypothesized by literature; however, we could identify also a novel 
relevant residue with such function 
For the first time, by combined approaches of molecular docking and 
molecular dynamic simulations, we demonstrated the crucial role of 
these residues in neutral amino acids transport. This novel information 
unravels new aspects of human SLC6A14 structure/function relationship 
and may have also important outcomes in cancer through the design of 
novel inhibitors of SLC6A14-mediated transport.
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Abstract
ATB0,+ (SLC6A14) is a sodium- and chloride-dependent neutral and dibasic amino acid transporter that 
regulates the distribution of amin  acids across cell membranes. SLC6A14 is ubiquitous. The transporter is 
over-expressed in many human cancers characterized by an increased demand for amino acids; as such, it was 
recently acknowledged as a novel target for cancer therapy. The knowledge on the molecular mechanism of 
SLC6A14 transport is still limited, but some elegant studies on related transporters report the involvement in 
the transport mechanism of the symmetry of the 12 transmembrane α-helices, and describe structural 
rearrangements mediated by electrostatic int ractions with some pivotal gating residues.
In the present work, we constructed a SLC6A14 model in outward facing conformation via homology 
modelling and tested through molecular dynamic simulation to predict amino acid residues critical for substrate 
recognition and translocation. We then docked the proteinogenic amino acids and other known substrates in 
the SLC6A14 binding site to study both gating regions and the exposed residues involved in transport. 
Interestingly, some of these residues correspond to those previously hypothesized by literature; however, we 
could identify also a novel relevant residue with such function
For the first time, by combined approaches of molecular docking and molecular dynamic simulations, we 
demonstrated the crucial role of these residues in neutral amino acids transport. This novel information 
unravels new aspects of human SLC6A14 structure/function relationship and may have also important 
outcomes in cancer through the design of novel inhibitors of SLC6A14-mediated transport.
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Introduction
Amino acids are the building blocks of protein synthesis (Sikder et al. 2018). They are essential components of all 
cells and are required for many metabolic pathways, nitrogen metabolism, neurotransmission and cell growth 
(Sikder et al. 2018; Scalise et al. 2016).  Due to their physicochemical properties, amino acids cannot pass freely 
across cell membranes but rather undergo carrier-mediated transmembrane movement by specific amino acid 
transporters. Mammalian cells express numerous amino acid transporters in their plasma membranes to enable 
intake and efflux of amino acids between each cell and the extracellular environment. Most amino acid 
transporters have a relatively narrow substrate specificity. However, there is one mammalian amino acid 
transporter that has an unusually broad substrate selectivity transporting 18 of the 20 proteinogenic amino acids 
(Sikder et al. 2018). This transporter was originally characterized in rabbit ileum and named the β-alanine carrier 
although it also transported a wide range of zwitterionic and dibasic amino acids (Munck and Schultz 1969). 
Separately, a broad-scope amino acid transporter was identified in preimplantation mouse blastocysts and named 
System B0,+ ((Van Winkle, Christensen, and Campione 1985). The transporter cDNA was cloned from human 
mammary gland and named ATB0,+ (Sloan and Mager 1999). ATB0,+  is a sodium- and chloride-dependent neutral 
and dibasic amino acid transporter which possesses all of the functional characteristics of both System B0,+ (Sloan 
and Mager 1999) and the β-alanine carrier (Anderson, Ganapathy, and Thwaites 2008) demonstrating that the 
early functional studies in intestine and blastocyst represent function of the same transport mechanism. 
Mammalian membrane transporters are categorized (based upon amino acid sequence identity) into 
SoLute Carrier (SLC) familes (Hediger et al. 2013). ATB0,+ is the 14th member of the SLC6 family and is also known 
as SLC6A14 (Bröer and Gether 2012). Although members of the SLC6 family show high levels of sequence identity 
between transporters, this family includes transporters with very different substrates where some are selective 
for amino acids and others are able to transport biogenic amines such as norepinephrine (NET/SLC6A2), dopamine 
(DAT/SLC6A3) or serotonin (SERT/SLC6A4) (Bröer and Gether 2012). The Transporter Classification Database 
(TCDB) of eukaryote and prokaryote transporters (Saier 2005), catalogues the human SLC6 transporters in the 
Neurotransmitter:Sodium Symporter family (NSS, TCDB family 2.A.22) which is within the broader Amino acid 
Polyamine organoCation (APC) Superfamily (Vastermark et al. 2014). 
ATB0,+ couples cotransport of 2 Na+, 1 Cl- and 1 amino acid, and is a highly concentrative electrogenic 
transport system with inward transmembrane amino acid transport being driven by membrane potential and Na+ 
and Cl- gradients (Sikder et al. 2018). ATB0,+ transports neutral amino acids and the dibasic amino acids arginine 
and lysine and thus transports all essential amino acids and only excludes the anionic amino acids glutamate and 
aspartate (Sikder et al. 2018). This broad substrate specificity also makes the ATB0,+ transporter accessible to a 
wide variety of amino acid-based drugs and prodrugs including valacyclovir (Hatanaka 2004), valganciclovir 
(Umapathy, Ganapathy, and Ganapathy 2004), 1-methyltryptophan (Karunakaran et al. 2008), nitric oxide 
synthase inhibitors (Hatanaka et al. 2001) and carnitine and analogues (Nakanishi et al. 2001). 
Abundant expression of ATB0,+ in healthy adult tissues is fairly restricted with expression mainly in retina, 
and respiratory and distal intestinal (ileum and colon) tissues where it is localized to luminal surfaces (Sikder et al. 
2018; Hatanaka 2004; Ugawa et al. 2001). In contrast, ATB0,+ expression is upregulated in many solid tumours 
including colorectal (Gupta et al. 2005), cervical (Gupta et al. 2006), estrogen receptor-positive breast 
(Karunakaran et al. 2011) and pancreatic (Coothankandaswamy et al. 2016) cancers. The high expression in cancer 
tissues alongside the broad substrate specificity make ATB0,+ a good target for anti-cancer treatments using small 
molecules.
The structure of ATB0,+ is unknown but like most members of the APC superfamily (Vastermark et al. 2014) 
it is predicted to possess a LeuT-fold core structure, named after the amino acid transporter LeuT, the first 
transporter crystallised from the APC superfamily (Yamashita et al. 2005). Other APC superfamily members have 
since been crystallised and have broadly similar folds including the human serotonin transporter SERT (SLC6A4) 
(Coleman, Green, and Gouaux 2016) and the Drosophila melanogaster dopamine transporter DAT (SLC6A3) 
(Penmatsa, Wang, and Gouaux 2015). ATB0,+ is predicted to have 12 transmembrane (TM) α-helices. Based upon 
available APC superfamily crystal structures, TM 1–5 and TM 6–10 are predicted to be involved in the transport 
mechanism and have an antiparallel symmetry in their secondary structures giving the α-helices a discrete mobility 
within the cell membrane and defining binding sites for transported substrates. The binding sites, S1 and S2, are 
located in the central binding pocket and in the extracellular vestibule, respectively (Kristensen et al. 2011). The 
central binding pocket must also contain sites that allow the binding of 2 Na+ and 1 Cl- ions. TM 11 and 12 are 
homologous to structures required for the homo-dimerization of other transporters, but currently no evidence is 
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available regarding ATB0,+ dimerization. For LeuT-fold proteins, a model of transport has been proposed (Gao et 
al. 2010): in the initial phase of the process, the protein lies in an “outward-facing” (OF) conformation and receives 
the transported substrate (and the ions) in binding site S2. The interaction between protein, ions and substrate 
promotes the translocation of transported solutes to the S1 binding site and closure of the gate. This process starts 
from the rotation of a specific conserved aromatic amino acid, which in turn leads to a conformational change in 
the whole protein, promoting its transition to an “inward-facing” (IF) conformation (Gao et al. 2010; Krammer et 
al. 2016). Afterwards, the substrate is released by the transporter in the intracellular space and the protein returns 
to the OF conformation, passing through intermediate transitory occluded states.
Therefore, the purpose of this investigation was to present for the first time the SLC6A14 3D structure, 
using homology modelling procedures to build a chimera model. Moreover, with this investigation, we meant: (i) 
to study in silico the structural features of the transporter, (ii) to identify in silico the key residues for the molecular 
recognition mechanism in the S1 binding site and (iii) to gather information about substrate binding. 
Materials and Methods
2.1. Comparative modelling of SLC6A14
The sequence of human SLC6A14 (Uniprot ID: Q9UN76) was retrieved from the Uniprot knowledgebase database 
(Li et al. 2015). After a protein Blast (Li et al. 2015) search in the Protein Data Bank database for a human SLC6A14 
homologue, the crystal structure of the Drosophila melanogaster sodium-dependent dopamine transporter (DAT) 
(PDB ID:4M48 ) (Penmatsa, Wang, and Gouaux 2015) was set as main template. A multiple alignment among the 
NSS family was produced with the Clustal Omega software (Larkin et al. 2007) and used for the homology 
modelling procedure. Since the crystal structure of DAT lacks the extracellular loop (EL) 2, a second local Blast 
search was set on residues S205-W270 of SLC6A14, identifying the crystallographic structure of 
phosphofructokinase (PFKA1) from Saccharomyces cerevisiae (PDB ID: 3O8O) (Banaszak et al. 2011) as an 
adequate template to fix the EL2 gap. The 3D structures of the two templates and of SLC6A14 were also 
investigated through both SWISS-MODEL and I-TASSER servers. Moreover, the transmembrane prediction 
programme TMHMM was used to determine the putative topology of SLC6A14, strenghtening the alignment 
between SLC6A14 and DAT from a structural point of view. PROTTER and was also used to build the prediction of 
secondary structure. 
Selected 3D structures were first optimized and refined via further computational steps by correcting 
crystallographic-related errors through the MOE Structure Preparation Module of the Molecular Operating 
Environment 2018 (MOE, Chemical Computing Group, Montreal, Canada). 
The selected portion (residues from L620 to R665) of phosphofructokinase template was carefully placed in the 
correspondence of DAT EL2. Three amino acids of both crystal structures were deleted at the point of connection 
between the two templates in order to have more flexibility to shape their junction in the chimeric model of 
SLC6A14, using the MOE Homology Model tool. Ten different intermediate models were built and submitted to 
energy minimization (EM) to release internal constraints. The top-scoring model, according to the GB/IV scoring 
function, was submitted to further EM with the ‘FINE’ option until the RMS gradient reached a value below 0.5 
kcal/mol/Å. 
The Amber10:ETH force field with the reaction-field model for electrostatics was applied for the whole modelling 
procedure.
2.2 Equilibration and cluster extrapolation
Molecular dynamics (MD) simulation and frame clustering procedures were carried out with the Schrödinger 
Small-Molecule Drug Discovery Suite 2018-01 (D. E. Shaw Research, New York, NY, 2018, Schrödinger, New York, 
NY, 2018).
The Desmond System Builder tool was used to place the apo-model of SLC6A14 into a POPC membrane bilayer. 
Protein orientation was set up according to the OPM server (Lomize et al. 2012), which provides spatial 
arrangements of membrane proteins with respect to the hydrocarbon core of the lipid bilayer. The N- and C-
termini of the protein were capped. The system was solvated with 10,174 SPC water molecules in a cubic box with 
90 Å edges; adding chloride ions neutralized the exceeding positive charge; sodium chloride was further added up 
to 0.15 M concentration. The system was energy-minimized to relax the assembly and remove clashes between 
protein, membrane and solvent in the new setup.
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To produce an equilibrated model of SLC6A14, the system was submitted to a 500 ns molecular dynamic 
simulation (MD) using Desmond Molecular Dynamics tool. Periodic boundary conditions (PBC) and the following 
parameters were set: 300 K and Nose-Hoover thermostat for temperature coupling, 1 bar and Martyna-Tobias-
Klein piston for pressure coupling, 2 fs as integration time step. Coordinates and velocities of each atom were 
saved every 0.5 ps. The trajectory was then analysed using both Desmond Simulation Event Analysis tool and VMD 
(Phillips et al. 2005).
Desmond Trajectory Frame Clustering tool was used to cluster the whole 500 MD simulation in order to select the 
most representative frame (the centroid) for each cluster. Distances between clusters were computed from the 
RMSD matrix of alpha carbons with respect to the first frame of the MD simulation. Two different runs were 
performed to set the number of generable clusters according to the dendrogram. 
The OPLS3e force field was applied both in the MD simulation and in the frame clusterization procedures. 
2.3 Docking
The centroid of the most populated cluster was selected as reference structure for molecular docking procedures. 
Water, ions and the POPC membrane were washed out from the system and three pivotal ions (1 Cl and 2 Na) 
from the DAT template were transferred to the SLC6A14 equilibrated model. The ions::SLC6A14 3D structure was 
then energy-minimized using the Prime in order to fix structural issues in the ions binding domain.
Tested ligands were downloaded from PubChem and prepared for docking with the Schrödinger Ligand 
Preparation.
The molecular docking procedure was carried out with the Schrödinger Glide Docking in the “extra precision (XP)” 
mode in order to evaluate the ability of the tested ligands to bind the SLC6A14 binding channel, keeping only the 
five top-scoring poses.
The top-scoring solution for each ligand was submitted to the Schrödinger Prime MM-GBSA, which integrates 
molecular mechanics energies with the generalized Born and surface area continuum solvation (Genheden and 
Ryde 2015) in order to compute ligand binding and ligand strain energies for a set of ligands and a single receptor.
The top-scoring solution for each ligand was also submitted to Desmond Molecular Dynamics tool for a 50 ns of 
MD simulation in order to study ligand::protein interaction and verify the stability of the ligand placement.
Periodic boundary conditions (PBC) and the following parameters were set for each MD simulation: 300 K and 
Nose-Hoover thermostat for temperature coupling, 1 bar and Martyna-Tobias-Klein piston for pressure coupling, 
2 fs as integration time step. Coordinates and velocities of each atom were saved every 0.5 ps. The trajectories 
were then analysed using Desmond Simulation Interaction Diagram tool and inspected through VMD.
The OPLS3e force field was applied both in molecular docking procedures and in MD simulations. 
Results and Discussion
3.1. Secondary structure analysis and two-dimensional topology prediction
None of the SLC6A14 homologous templates provides complete sequence coverage, as all of them leave out EL2. 
Not unexpectedly, the SWISS-MODEL and the I-TASSER predictions on the whole protein are unsatisfactory 
because, in both cases, the EL2 is predicted at an exceedingly high distance from a theoretical conformation 
resulting in very low local quality estimation. A very high number (>30) of outliers is observed in both 
Ramachandran plots. Supplementary Figure 1 reports the SWISS-MODEL quality estimation plot and the I-TASSER 
estimation distance plot.
Building a chimera model seems then to be the right strategy to study SLC6A14 at an atomistic level.
Taking the global alignment among members of the NSS family as the reference structure to model SLC6A14 in its 
OF conformation, we selected DAT (Penmatsa, Wang, and Gouaux 2015), with a sequence identity of 43% and a 
similarity of 59%, as the most suitable template presently available. Moreover, unlike other suitable templates 
whose structure contains only one cation and one anion, DAT is co-crystallized with 2 Na+ ions and 1 Cl- ion. On 
the other hand, according to BLAST, PFKA1, with a local sequence identity of 28% and local similarity of 46%, 
appears to be the most suitable template for modelling EL2.
The second step towards building a chimera model of SLC6A14 was to compare its putative secondary structure 
and the two-dimensional topology predicted with three independent methods, while taking into account both the 
alignment and the topology of the DAT crystal (Penmatsa, Wang, and Gouaux 2015). Figure 1 shows the alignment 
among SLC6A14 and the selected templates; SLC6A14 is annotated according to TMHMM and PROTTER prediction.
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Figure 1
PROTTER and TMHMM prediction are compliant with the DAT secondary structure and its transmembrane 
placement. In particular, the first three TM α-helices of DAT are more extended than expected from the prediction, 
while TM α-helices from 4 to 7 and from 9 to 12 are in good agreement with the expectations. TM α-helix 8 seems 
to be shifted towards the C-terminus by 5 amino acids with respect to PROTTER prediction, while it complies with 
TMHMM prediction. The alignment among SLC6A14, DAT and PFKA1 was carefully verified taking into account 
also the PROTTER and TMHMM prediction. Predicted topology of SLC6A14 is shown in Figure 2.
Figure 2
3.2. Homology modelling of SLC6A14 and its MD equilibration
The Ramachandran plot for the chimera model of SLC6A14, based on both DAT and PFKA1, shows only six outliers, 
none of them in the transmembrane domain (Supplementary Figure 2.A). Its secondary structure is compliant with 
both the DAT structure and the PROTTER and TMHMM predictions. As expected, SLC6A14 model has a LeuT-fold, 
with two well defined binding sites for both substrate/inhibitor and Na+/Cl- ions, respectively.
In order to equilibrate the chimera model of SLC6A14, we carried out a 500 ns MD simulation. The evaluation of 
the stability of our model during the simulation was based both on energetic and geometric parameters, as 
described in the following. 
The general stability of the SLC6A14 model is confirmed by the tendency of the MD simulations to reach 
convergence. In detail, the tendency to reach an equilibrium state is suggested by the trend of the root mean 
square deviation (RMSD) values, which, after 100 ns, reach a plateau around 3.5 Å (Figure 3.A); its fluctuations 
towards the end of the simulation are around some thermal average structure. The lowest root mean square 
fluctuations (RMSF) are associated with α-helices, the highest with the loops, both inter- and extra-cellular, with 
maximum in EL2 (Figure 3.B).
Figure 3
Protein secondary structure elements (SSE) i.e. α-helices and β-strands, were monitored throughout the 
simulation. Figure 3.C reports SSE distribution by residue index, while Figure 4 summarizes the SSE composition 
for each trajectory frame over the course of the simulation and monitors each residue and its SSE assignment over 
time. Globally, the secondary structure of SLC6A14 is conserved during the MD simulation; the helices in EL2 are 
structured in over 50% of the frames, despite EL2 undergoing a strong rearrangement during the first 200 ns. In 
fact, EL2 migrates from a conformation extended towards the extracellular side to a more stable situation 
(Supplementary Figure 3), in which it establishes some H-bonds with the exposed amino acids of other ELs. Asn219 
interacts with Lys225 via an H-bond, that is conserved for ~ 70% of the frames, shaping a turn-like structure and 
partially covering the SLC6A14 transport channel. This peculiar shape of EL2 is present in the frame selected for 
structural analysis, that is the centroid of the most populated cluster, composed by ~70% of the all frames. The 
Ramachandran plot of the selected frame shows only one outlier (Supplementary Figure 2.B). 
Figure 4
3.3 Structural features of the binding sites
Figure 5
To study the structural features of SLC6A14 transport channel, and its binding sites, we imported from DAT crystal 
structure to our SLC6A14 equilibrated model two Na+ and one Cl- ions and, then, we relaxed the protein to avoid 
atom clashes. Figure 5 shows the SLC6A14 equilibrated structure after the local minimization of the ion pocket. 
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As mentioned in the Introduction, it is well known that, when in OF conformation, SLC6A family members have a 
binding site in the bottom of their transport channel. This binding site includes two specific regions: the first for 
the substrate, the second for the co-transported ions, which are a fundamental feature of all the SLC6 
transporters.
In SLC6A14 we found two distinct sites in the S1 pocket that are unambiguously being occupied by a Na+ ion, 
designated Na1 and Na2 (Singh 2008). Both Na+ binding sites are believed to have a key role in stabilizing TM1 and 
TM6 in the presence of substrate. 
Na1 binding site is closed towards the Cl- binding site, and is divided from Na2 by TM1, sharing some amino acids 
with it. Na1 is not contiguous with the S1 substrate binding site, while the Na1 site insists on the S1 substrate 
binding site, and the Na+ ion is available for interacting with the substrate. Residues composing the Na1 and Na2 
ion binding sites are conserved among the transporters of interest and, in general, are highly conserved across the 
whole SLC6 family (Kristensen et al. 2011). As suggested by Kristensen (Kristensen et al. 2011), the evidence of 
contiguous surfaces between Na2 and the substrate binding site can be the basis for a coupled translocation 
mechanism for both, Na+ and substrate. On the other hand, the placement of Cl- in the Na1 binding site supports 
the idea that Cl- is translocated together with the Na+ ion along the SLC6A14 channel during the transport of the 
substrate. The same ion placement has been reported also for the crystallographic structures of DAT (SLC6A3) and 
human SERT (SLC6A4) (Penmatsa, Wang, and Gouaux 2015; Coleman, Green, and Gouaux 2016). These data 
confirm that our equilibrated SLC6A14 model maintains its ion binding site (Figure 6.A).
Figure 6
The S1 substrate binding site is defined by polar, aromatic, and aliphatic amino acid side chains provided by all 
four TMs (TM1, TM3, TM6, and TM8) that surround the binding site, in addition to the backbone amide groups 
from the unwound regions of TM1 and TM6 (Singh 2008). The S1 pocket can be divided into two regions: a polar 
region formed exclusively by the unwound regions of TM1 and TM6 and a hydrophobic pocket formed by aliphatic 
side chains from TM1, TM3, and TM6 (Figure 6.B).
In the SLC6A14 equilibrated model, we can also detect the S2 binding site in the gating region (Kristensen et al. 
2011), which is partially defined at the bottom by three amino acids: Tyr321, Arg61and Asp478, which are partially 
conserved among SLC6A14, DAT and SLC6A4 (Figure 6.B).
Arg104 and Asp478 establish a H-bond, fixing the Arg104 in a conformation stretched toward the inside of the 
transport channel. Tyr321 is stretched toward the transport channel, unlike its corresponding amino acids Phe319 
and Phe335 in DAT and SLC6A14, respectively.
From a structural point of view, this particular aromatic amino acid seems to assume the same function of Trp202, 
the gating residue of the arginine/agmatine antiporter AdiC. This gating mechanism is also supposed to be 
conserved for the SLC6 family (Pramod et al. 2013) and it was simulated for LAT1 (SLC7A5) via target molecular 
dynamics (Palazzolo et al. 2018). To evaluate the gating arrangement, we compared the placement of Phe319 in 
two DAT crystallographic structures in OF conformation, with gate open (Pdb ID: 4M48 ) (Penmatsa, Wang, and 
Gouaux 2015) and closed (Pdb ID: 4XPA) (Wang, Penmatsa, and Gouaux 2015), via a structural superposition. As 
shown in Figure 9.A, Tyr321 of the equilibrated model of SLC6A14 is in an intermediate position between DAT 
Phe319 open and closed conformations, suggesting that this amino acid has an intrinsic flexibility also in the 
absence of substrates/inhibitors. This intrinsic flexibility is also observed during the MD simulation, during which 
Tyr321 oscillates between open and partially closed conformation, with respect to DAT as a reference (Figure 7.A), 
suggesting that this amino acid has many degrees of freedom while it explores the conformational spaces in its 
surroundings. 
Figure 7
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Moreover, we also identified the Trp327 as second putative inner gate of SLC6A14. In particular, this amino acid 
rotates from a DAT Phe325-like conformation to an occluded one, defining the bottom of the S1 substrate binding 
site. Evidence that Trp327 can be involved in the inner gating mechanism can be obtained from a structural 
analysis of the DAT Phe325 behaviour in presence of different inhibitors. As shown in Figure 7.B, DAT Phe325 has 
some degrees of freedom to coordinate itself with the transported molecules. In the two reference 
crystallographic structures of DAT, Phe325 is oriented by the inhibitors and it is alternately open or closed, with 
Phe319 behaving as the outer gate.
 
3.4 Molecular docking
As mentioned in the introduction, there are some aa transporters, among which SLC6A14, that transports 18 of 
the 20 amino acids, i.e. all of the proteogenic amino acids except glutamate and aspartate (Scalise et al. 2016).
Molecular docking simulation was applied to place the substrates into the S1 binding site, appraising 
substrate::carrier interactions and computing the relevant docking scores. On the basis of these results, each 
complex substrate::carrier was submitted to a 50 ns MD simulation to evaluate the stability of the interactions 
and to assess the molecular recognition mechanisms, looking for pivotal amino acids involved in the recognition 
of the different substrates.
As expected, most of the tested ligands have docking scores ranging from -8 kcal/mol to -1 kcal/mol, values that 
are compliant with solute transport. Supplementary Table 1 reports the most interesting interactions between 
tested compound and SLC6A14 amino acids during the MD simulations.
Tryptophan and 1-methyl-L-tryptophan are the substrates associated with the best docking scores, i.e. -7.5 
kcal/mol and -6.3 kcal/mol, respectively. These substrates are placed into the S1 binding site with overlapping 
docking poses (Figure 8); their interactions are mainly with Tyr321, Trp327, Phe320, Ser324, Leu56 and Ser423. 
The MD simulations show that the most conserved contacts between tryptophan and SLC6A14 amino acids are 
with Tyr52, Ala53, Gly57, Tyr132 and Tyr321 and that all of these contacts occur via H-bonds. On the other hand, 
1-methyl-L-tryptophan interacts via H-bonds with Leu56, Gly57, Tyr132, Phe320 and Ser324, and all of these 
contacts are conserved during the MD simulation. Ala53 establishes an important ionic interaction with 1-methyl-
L-tryptophan that is conserved in the whole MD simulation. Both substrates interact also with Na+ in the Na1 ion 
binding site for ~97% of the simulation total frames. These results are in agreement with those of both Hatanaka 
et al. (2004) and Karunakaran et al. (2008). 
Figure 8
Tyrosine overlap the Tryptophan docking pose, with associated a docking score of -5.4 kcal/mol, mainly interacting 
with Ala326 and Ser324. The MD simulation highlight also H-bonds interaction with Val54, Leu56, Ser324 and Ser 
423 and other important hydrophobic interactions with Tyr132, Tyr321, Trp327. 
Arginine, Leucine and Isoleucine share the same binding pose and have similar docking scores of -4.9 kcal/mol, -
4.6 kcal/mol and -4.4 kcal/mol, respectively. Arginine mainly interacts with Tyr132, Phe320 and Asp478, while 
Leucine and Isoleucine establishes H-bonds with Tyr132, Phe320, Val325 and Ser324. The MD simulations show 
that Asp478 is the pivotal binder for Arginine and it is probably involved also in the recognition mechanism, while 
for Leucine and IsoleucineTyr321 is the pivotal amino acid with which interacts for ~ 94% of the MD simulation. 
Arginine interacts with Cl-, while Leucine interacts with Na+ in the Na1 ions binding site.
As reported in Scalise et al. (2016), Glutamine is compressed between Val128 and Tyr321, with a docking score 
value of -3.8 kcal/mol. Glutamine also interacts via H-bonds with Tyr132, Phe320 and Asp478 in its binding pose, 
while the MD simulation detects ionic interactions with Ala53, Tyr321 and Ser324. Glutamine also interacts with 
Na+ in the Na1 ion binding site.
Proline and Cysteine have very similar both binding poses and docking scores of about -3.1 kcal/mol. This tested 
amino acids share the same interaction with Tyr132 and Phe320, establishing four H-bonds during the MD 
simulations also with Ser324 and Val325. Contact with Tyr132, Phe320 and Ser324 are conserved for both 
substrates for over 90% of the total time of the MD simulations.
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Carnitine shows a completely different binding pose with respect to the tested amino acids one, with associated 
a docking score of -1.4 kcal/mol. From the ligand interaction diagram of molecular docking, it interacts with Leu56 
and Ser423 via H-bonds, while during the MD simulation it shift in the S1 binding pocket from Ser478 to the S1 ion 
binding site, interacting with Na+. In this context, Carnitine interacts with Tyr95, Leu99, Gly100, Tyr176, Trp381, 
Tyr375 and Ser378.
Finally, the two prodrugs valganciclovir and valaciclovir have dissimilar behaviour in their binding poses. Despite 
their binding poses partly overlapping, the docking score is -5.2 kcal/mol for the former, and -1.2 kcal/mol, for the 
latter. Both substrates interact with Asp478, Tyr321 and Tyr132 but Valganciclovir establishes also some contacts 
with Tyr52, Leu56 and Asp477. The MD simulations show for both substrates that those with Tyr132 and Asp478 
are the most conserved H-bonds interactions, together with Leu56, Ala537 and Ser324. None of them interact 
with Na+ or Cl- ions. 
For all the tested substrates, also Val172 is always involved via a hydrophobic interaction. In fact, this amino acid 
is part of the S1 binding site, and it sterically occupies part of the pocked with its side chain. Moreover, arginine 
and its derivatives, glutamine and both the test prodrugs are coordinated by Asp478 that is placed in the upper 
part of the S1 binding site, together with Tyr321 that is pivotal in all the interactions. These data suggest that 
Tyr321 can act as gate, involving also the Asp478, while other aromatic and aliphatic side chains of amino acids in 
S1 are involved in the recognition and transport mechanism of substrates trough the SLC6A14 channel.
Conclusions
With our research, we propose, the first atomistic model of SLC6A14 transporter based on a chimeric approach: 
the two templates selected for modelling the OF SLC6A14 state are the most suitable so far available, and one of 
them has also been profitably used in a recent publication (Scalise et al. 2016). Thanks to 500 ns of MD simulation, 
we identified a specific behaviour of Tyr321, highlighting its role in the outer gating mechanism that is coordinated 
with the involvement of Arg104 and Asp478. We also identified Trp327 as putative inner gate, in analogy to DAT, 
our reference template. These two amino acids define the S1 binding site while Tyr321 is at the same time at the 
bottom of the S2 binding site. From the cluster analysis we selected a reference 3D structure of SLC6A14 and we 
observed that ions binding sites are conserved across the SLC6 family. 
Natural amino acids and some other well-known substrates were tested for interaction via molecular docking 
simulation. For all of them both the docking scores were evaluated, and the molecular recognition mechanism 
was characterized, highlighting that both gates are essential for binding. In a broader way, Try52, Gly57, Val128, 
Ser322 and Ser324 compose an ensemble of amino acids that orient the substrates, confirming the structural 
findings of Yamashita et al. (2005), Scalise et al. (2016) and Edwards et al. (2018). 
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Figure 1. Alignment among SLC6A14, DAT and PFKA1. TMHMM and PROTTER prediction are marked as violet bar, 
while secondary structure i.e. α-helices and β-sheets of both DAT and PFKA1 are coloured in red and yellow, 
respectively.
Figure 2. 2D topology and transmembrane prediction for SLC6A14. Results with PROTTER are shown in (A), with 
TMHMM in (B). In (A) transmembrane helices are numbered from 1 to 12 and the putative N-linked glycosylation sites 
is marked in green.
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Figure 3: Stability of SLC6A14 model. (A) Root mean square deviation of SLC6A14 α-carbon computed for each frame of 
MD simulation with respect to frame 0. (B) Root mean square fluctuation of SLC6A14 α-carbon during the MD 
simulation. (C) Secondary structure elements: α-helical regions are highlighted in red These regions are defined by 
helices that persist over 70% of the entire simulation.
Figure 4: Stability of SLC6A14 model. (Too) Root mean square deviation of SLC6A14 α-carbons computed for each frame 
of MD simulation with respect to frame 0. (Bottom) Root mean square fluctuation of SLC6A14 α-carbon during the MD 
simulation. (C) Secondary structure elements. α-helical regions, defined as structures that persist over 70% of the entire 
simulation, are highlighted in red.
Figure 5. SLC6A14 equilibrated model. (A) Transversal view, (B) bottom and (C) top views. Secondary structure is 
represented by ribbons and coloured from N (blue) to C terminus (red); ions are represented as balloons. 
Figure 6: SLC6A14 binding sites. (A) Ions binding site, and (B) S1 and S2 substrate binding site surfaces in SLC6A14. 
Putative amino acids involved in the gating mechanism are outlined. The molecular surfaces of SLC6A14 binding 
sites computed as van der Waals interaction surface are represented with green, magenta and blue lines for 
hydrophobic, H-bonding and mild polar interactions, respectively.
Figure 7: (A) Outer gate of SLC6A14 and its superposition to DAT crystallographic structures both in OF-open and 
OF-closed conformations. (B) SLC6A14 and DAT gates; as for other APCs, SLC6A14 seems to have two distinct 
aromatic amino acids that are involved in the gating mechanism. SLC6A14, DAT OF-open and DAT OF-closed are 
represented in yellow, light blue and light green, respectively.
Figure 8: (A) Tryptophan and 1-methyl-L-tryptophan, and (B) valaciclovir and valganciclovir binding poses. SLC6A14 
helices and gating amino acids are coloured in yellow.
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TMHMM                                                                
PROTTER                                                              
S6A14_HUMAN     1 MDKLKCPSFFKCREKEKVSASSENFHVG--------ENDEN---QDRGNW     39 
DAT_DROME       1 --------------------MSPTGHISKSKTPTPHDNDNNSISDERETW     30 
 
TMHMM                                                                
PROTTER                                                              
S6A14_HUMAN    40 SKKSDYLLSMIGYAVGLGNVWRFPYLTYSNGGGAFLIPYAIMLALAGLPL     89 
DAT_DROME      31 SGKVDFLLSVIGFAVDLANVWRFPYLCYKNGGGAFLVPYGIMLAVGGIPL     80 
 
TMHMM                                                               
PROTTER                                                             
S6A14_HUMAN    90 FFLECSLGQFASLGPVSVW-RILPLFQGVGITMVLISIFVTIYYNVIIAY    138 
DAT_DROME      81 FYMELALGQHNRKGAITCWGRLVPLFKGIGYAVVLIAFYVDFYYNVIIAW    130 
 
TMHMM                                                                
PROTTER                                                              
S6A14_HUMAN   139 SLYYMFASFQSELPWKNCSS-WSDKNC--------SRSPIVTHCNVSTV-    178 
DAT_DROME     131 SLRFFFASFTNSLPWTSCNNIWNTPNCRPFESQNASRVPVIG--NYSDLY    178 
PFK1_YEAST    616 -----------------------------------TLYCLSHGHKPYAIM    630 
 
TMHMM                                                                
PROTTER                                                              
S6A14_HUMAN   179 NKGIQEIIQMNK---SWVDINNFTCINGSEI----YQPGQLPSEQYWNK-    220 
DAT_DROME     179 AMGNQSLLY---------NETYMNGSSLDTSAVGHVEGFQSAASEYFNRY    219 
PFK1_YEAST    631 NGFSGLIQTGEVKELSWIDVENWHNLGGSEI----GTNR-----------    665 
 
TMHMM                                                                
PROTTER                                                              
S6A14_HUMAN   221 -VALQRSSGMNETGVIVWYLALCLLLAWLIVGAALFKGIKSSGKVVYFTA    269 
DAT_DROME     220 ILELNRSEGIHDLGAIKWDMALCLLIVYLICYFSLWKGISTSGKVVWFTA    269 
 
TMHMM                                                                
PROTTER                                                              
S6A14_HUMAN   270 LFPYVVLLILLVRGATLEGASKGISYYIGAQSNFTKLKEAEVWKDAATQI    319 
DAT_DROME     270 LFPYAVLLILLIRGLTLPGSFLGIQYYL--TPNFSAIYKAEVWVDAATQV    317 
 
TMHMM                                                                
PROTTER                                                              
S6A14_HUMAN   320 FYSLSVAWGGLVALSSYNKFKNNCFSDAIVVCLTNCLTSVFAGFAIFSIL    369 
DAT_DROME     318 FFSLGPGFGVLLAYASYNKYHNNVYKDALLTSFINSATSFIAGFVIFSVL    367 
 
TMHMM                                                                
PROTTER                                                              
S6A14_HUMAN   370 GHMAHISGKEVSQVVKSGFDLAFIAYPEALAQLPGGPFWSILFFFMLLTL    419 
DAT_DROME     368 GYMAHTLGVRIEDVATEGPGLVFVVYPAAIATMPASTFWALIFFMMLLTL    417 
 
TMHMM                                                                
PROTTER                                                              
S6A14_HUMAN   420 GLDSQFASIETITTTIQDLFPKVMKKMRVPITLGCCLVLFLLGLVCVTQA    469 
DAT_DROME     418 GLDSSFGGSEAIITALSDEFPKI-KRNRELFVAGLFSLYFVVGLASCTQG    466 
 
TMHMM                                                                
PROTTER                                                              
S6A14_HUMAN   470 GIYWVHLIDHFCAGWGILIAAILELVGIIWIYGGNRFIEDTEMMIGAKRW    519 
DAT_DROME     467 GFYFFHLLDRYAAGYSILVAVFFEAIAVSWIYGTNRFSEDIRDMIGFPP-    515 
 
TMHMM                                                                
PROTTER                                                              
S6A14_HUMAN   520 IFWLWWRACWFVITPILLIAIFIWSLVQFHRPNYGAIPYPDWGVALGWCM    569 
DAT_DROME     516 --GRYWQVCWRFVAPIFLLFITVYGLIGYEPLTYADYVYPSWANALGWCI    563 
 
TMHMM                                                                
PROTTER                                                              
S6A14_HUMAN   570 IVFCIIWIPIMAIIKIIQAKGNIFQR---LISCCRPASNWGPYLEQHRGE    616 
DAT_DROME     564 AGSSVVMIPAVAIFKLLSTPGSLRQRFTILTTPWRDQQSMAMVLNGVTTE    613 
 
TMHMM                                            
PROTTER                                          
S6A14_HUMAN   617 ----RYKDMVDPKKEADHEIPTVSGSRKPE                        642 
DAT_DROME     614 VTVVRLTDTETAKEPVDV------------                        631 
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Supplementary Figure 1: (A) Local quality estimation of Swiss Model results and (B) I-Tasser 
estimated distance between model and theoretical folding. 
 
 
  
 
Supplementary Figure 2: Ramachandran plot of SLC6A14 chimera model before (A) and after (B) 
the molecular dynamics equilibration. 
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Supplementary Figure 3: Superposition of SLC6A14 conformations (A) with a focus on EL2 (B). In 
yellow is depicted the SLC6A14 structure from homology modelling procedure, before to be 
submitted to 500 ns MD equilibration; in blue the centroid of the most populated cluster. It is evident 
the structural rearrangement of EL2. 
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Arg Gln Gly 1-met-Trp Phe Trp
Gly 51
Tyr 52 WB WB H WB H
Ala 53 I I I HB
Val 54 WB
Gly 55 I I I HB
Leu 56 WB H HB HB HB
Gly 57 I H WB HB HB
Asn 58 I I
Trp 60 H H
Arg 61 WB WB
Ile 124 H
Val 128 H H H H
Tyr 131 WB WB HB
Tyr 132 HB HB HB HB H WB 
Ile 135
Thr 317 WB WB
Gln 318 WB
Phe 320 HB HB WB HB WB HB
Tyr 321 H I H H I
Ser 322 I WB I I I
Ser 324 HB i H HB I HB
Val 325 HB WB
Ala 326 HB WB
Trp 327 H H H H H
Asn 354 I
Phe 388 H
Leu 419 WB
Gly 420 WB
Asp 422
Ser 423 WB WB WB WB WB
Gln 424 WB
Ile 477 WB
Asp 478 HB HB WB
Cys 481 WB HB
Ala 482 WB H
Ile 486 H H H
I Ionic
HB H-bond
H Hydrophobic
WB Water Bridge
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Tyr valaciclovir valganciclovir Leu His Pro
Gly 51 HB
Tyr 52 H H H H H WB
Ala 53 I H I
Val 54 HB I
Gly 55 WB
Leu 56 HB HB HB HB
Gly 57 HB WB HB HB
Asn 58 I
Trp 60 WB H
Arg 61 WB H HB WB
Ile 124
Val 128 H H H H H
Tyr 131 WB WB H
Tyr 132 H HB HB HB HB HB
Ile 135 H
Thr 317 WB
Gln 318
Phe 320 H WB WB WB HB HB
Tyr 321 H H H H I I
Ser 322 I I
Ser 324 HB HB HB WB I HB
Val 325 WB WB HB HB
Ala 326 WB HB
Trp 327 H H H H H H
Asn 354
Phe 388
Leu 419 HB
Gly 420 WB HB
Asp 422 H HB HB
Ser 423 HB HB WB
Gln 424 WB
Ile 477 HB HB
Asp 478 WB HB HB WB
Cys 481 WB HB HB
Ala 482 HB HB WB H
Ile 486 H H H H
I Ionic
HB H-bond
H Hydrophobic
WB Water Bridge
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Tre Ala Carnitine Cys
Gly 51 HB
Tyr 52 WB I WB
Ala 53 I I
Val 54 HB
Gly 55 I HB WB
Leu 56 HB HB
Gly 57 HB I
Asn 58
Trp 60 WB H WB
Arg 61 WB WB
Ile 124 H H
Val 128 H
Tyr 131 WB HB HB
Tyr 132 HB HB HB
Ile 135 H
Thr 317 WB
Gln 318
Phe 320 HB WB I HB
Tyr 321 WB I I I
Ser 322 I I HB
Ser 324 WB I HB
Val 325 WB HB
Ala 326 WB WB H
Trp 327 H H I H
Asn 354
Phe 388
Leu 419
Gly 420
Asp 422 HB
Ser 423 WB WB
Gln 424
Ile 477
Asp 478 WB I
Cys 481
Ala 482 WB H
Ile 486 H H
I Ionic
HB H-bond
H Hydrophobic
WB Water Bridge
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